Wyeth Pharmaceuticals received approval from the FDA for Tygacil (tigecycline) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by susceptible strains of indicated pathogens. The drug was first approved by the FDA in 2005 for the treatment of complicated intra-abdominal infections (cIAI) and complicated skin and skin structure infections (cSSSI) in adults. CABP infects an estimated 4.5 million people each year. “The approval of this new indic...